Ionis Pharmaceuticals (IONS) Projected to Post Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 19th. Analysts expect Ionis Pharmaceuticals to post earnings of ($1.09) per share and revenue of $140.97 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Ionis Pharmaceuticals Trading Up 2.3 %

Shares of IONS stock traded up $0.69 on Friday, hitting $31.04. 1,445,661 shares of the company's stock traded hands, compared to its average volume of 1,668,259. The stock has a market capitalization of $4.90 billion, a price-to-earnings ratio of -12.72 and a beta of 0.34. The company's fifty day simple moving average is $34.22 and its 200 day simple moving average is $38.89. Ionis Pharmaceuticals has a one year low of $30.23 and a one year high of $52.34. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91.

Wall Street Analyst Weigh In

IONS has been the topic of several recent research reports. Piper Sandler reduced their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. William Blair restated an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Royal Bank of Canada reiterated an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. StockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.65.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, EVP Patrick R. O'neil sold 6,165 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the transaction, the executive vice president now directly owns 57,452 shares of the company's stock, valued at approximately $1,816,632.24. This represents a 9.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 33,445 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.35. Following the completion of the sale, the chief executive officer now directly owns 207,396 shares of the company's stock, valued at approximately $6,767,331.48. The trade was a 13.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,609 shares of company stock worth $3,564,867. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.